These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 32577668)

  • 61. Improving precision by adjusting for prognostic baseline variables in randomized trials with binary outcomes, without regression model assumptions.
    Steingrimsson JA; Hanley DF; Rosenblum M
    Contemp Clin Trials; 2017 Mar; 54():18-24. PubMed ID: 28064029
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Efficacy and safety of nelfinavir in asymptomatic and mild COVID-19 patients: a structured summary of a study protocol for a multicenter, randomized controlled trial.
    Hosogaya N; Miyazaki T; Fukushige Y; Takemori S; Morimoto S; Yamamoto H; Hori M; Kurokawa T; Kawasaki Y; Hanawa M; Fujii Y; Hanaoka H; Iwami S; Watashi K; Yamagoe S; Miyazaki Y; Wakita T; Izumikawa K; Yanagihara K; Mukae H; Kohno S;
    Trials; 2021 Apr; 22(1):309. PubMed ID: 33910617
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Leveraging baseline covariates to analyze small cluster-randomized trials with a rare binary outcome.
    Zhu AY; Mitra N; Hemming K; Harhay MO; Li F
    Biom J; 2024 Jan; 66(1):e2200135. PubMed ID: 37035941
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The UPMC OPTIMISE-C19 (OPtimizing Treatment and Impact of Monoclonal antIbodieS through Evaluation for COVID-19) trial: a structured summary of a study protocol for an open-label, pragmatic, comparative effectiveness platform trial with response-adaptive randomization.
    Huang DT; McCreary EK; Bariola JR; Wadas RJ; Kip KE; Marroquin OC; Koscumb S; Collins K; Shovel JA; Schmidhofer M; Wisniewski MK; Sullivan C; Yealy DM; Axe M; Nace DA; Haidar G; Khadem T; Linstrum K; Snyder GM; Seymour CW; Montgomery SK; McVerry BJ; Berry L; Berry S; Meyers R; Weissman A; Peck-Palmer OM; Wells A; Bart R; Albin DL; Minnier T; Angus DC
    Trials; 2021 May; 22(1):363. PubMed ID: 34034784
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Inference on covariate effect types for treatment effectiveness in a randomized trial with a binary outcome.
    Chiba Y
    Clin Trials; 2019 Jun; 16(3):237-245. PubMed ID: 30760066
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A structured summary of a study protocol for a multi-center, randomized controlled trial (RCT) of COVID-19 prevention with Kampo medicines (Integrative Management in Japan for Epidemic Disease by prophylactic study: IMJEDI P1 study).
    Namiki T; Takayama S; Arita R; Ishii T; Kainuma M; Makino T; Mimura M; Yoshino T; Nogami T; Arai M; Sato J; Tanaka K; Nakae H; Igari H; Ozawa Y; Shiko Y; Kawasaki Y; Nezu M; Ito T
    Trials; 2021 Jan; 22(1):23. PubMed ID: 33407828
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial.
    Lyngbakken MN; Berdal JE; Eskesen A; Kvale D; Olsen IC; Rangberg A; Jonassen CM; Omland T; Røsjø H; Dalgard O
    Trials; 2020 Jun; 21(1):485. PubMed ID: 32503662
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial.
    Garcia-Vicuña R; Abad-Santos F; González-Alvaro I; Ramos-Lima F; Sanz JS
    Trials; 2020 Sep; 21(1):772. PubMed ID: 32907638
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effect of dexamethasone in patients with ARDS and COVID-19 - prospective, multi-centre, open-label, parallel-group, randomised controlled trial (REMED trial): A structured summary of a study protocol for a randomised controlled trial.
    Maláska J; Stašek J; Duška F; Balík M; Máca J; Hruda J; Vymazal T; Klementová O; Zatloukal J; Gabrhelík T; Novotný P; Demlová R; Kubátová J; Vinklerová J; Svobodník A; Kratochvíl M; Klučka J; Gál R; Singer M;
    Trials; 2021 Mar; 22(1):172. PubMed ID: 33648568
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Increasing the efficiency of randomized trial estimates via linear adjustment for a prognostic score.
    Schuler A; Walsh D; Hall D; Walsh J; Fisher C; ; ;
    Int J Biostat; 2022 Nov; 18(2):329-356. PubMed ID: 34957728
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Genomic and clinical predictors for improving estimator precision in randomized trials of breast cancer treatments.
    Patil P; Colantuoni E; Leek JT; Rosenblum M
    Contemp Clin Trials Commun; 2016 Aug; 3():48-54. PubMed ID: 29736456
    [TBL] [Abstract][Full Text] [Related]  

  • 72. ACCORD: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalised Patients: A structured summary of a study protocol for a randomised controlled trial.
    Wilkinson T; Dixon R; Page C; Carroll M; Griffiths G; Ho LP; De Soyza A; Felton T; Lewis KE; Phekoo K; Chalmers JD; Gordon A; McGarvey L; Doherty J; Read RC; Shankar-Hari M; Martinez-Alier N; O'Kelly M; Duncan G; Walles R; Sykes J; Summers C; Singh D;
    Trials; 2020 Jul; 21(1):691. PubMed ID: 32736596
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Covariate Adjustment in Cardiovascular Randomized Controlled Trials: Its Value, Current Practice, and Need for Improvement.
    Pirondini L; Gregson J; Owen R; Collier T; Pocock S
    JACC Heart Fail; 2022 May; 10(5):297-305. PubMed ID: 35483791
    [TBL] [Abstract][Full Text] [Related]  

  • 74. muLTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19-Experimental drugs and mechanisms (TACTIC-E): A structured summary of a study protocol for a randomized controlled trial.
    Lu IN; Kulkarni S; Fisk M; Kostapanos M; Banham-Hall E; Kadyan S; Bond S; Norton S; Cope A; Galloway J; Hall F; Jayne D; Wilkinson IB; Cheriyan J
    Trials; 2020 Jul; 21(1):690. PubMed ID: 32736592
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Pakistan Randomized and Observational Trial to Evaluate Coronavirus Treatment (PROTECT) of Hydroxychloroquine, Oseltamivir and Azithromycin to treat newly diagnosed patients with COVID-19 infection who have no comorbidities like diabetes mellitus: A structured summary of a study protocol for a randomized controlled trial.
    Akram J; Azhar S; Shahzad M; Latif W; Khan KS
    Trials; 2020 Aug; 21(1):702. PubMed ID: 32771032
    [TBL] [Abstract][Full Text] [Related]  

  • 76. COVIDENZA - A prospective, multicenter, randomized PHASE II clinical trial of enzalutamide treatment to decrease the morbidity in patients with Corona virus disease 2019 (COVID-19): a structured summary of a study protocol for a randomised controlled trial.
    Welén K; Överby AK; Ahlm C; Freyhult E; Robinsson D; Henningsson AJ; Stranne J; Bremell D; Angelin M; Lindquist E; Buckland R; Carlsson CT; Pauksens K; Bill-Axelsson A; Akre O; Ryden C; Wagenius M; Bjartell A; Nilsson AC; Styrke J; Repo J; Balkhed ÅÖ; Niward K; Gisslén M; Josefsson A
    Trials; 2021 Mar; 22(1):209. PubMed ID: 33726804
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A multi-center, randomized controlled trial by the Integrative Management in Japan for Epidemic Disease (IMJEDI study-RCT) on the use of Kampo medicine, kakkonto with shosaikotokakikyosekko, in mild-to-moderate COVID-19 patients for symptomatic relief and prevention of severe stage: a structured summary of a study protocol for a randomized controlled trial.
    Takayama S; Namiki T; Ito T; Arita R; Nakae H; Kobayashi S; Yoshino T; Ishigami T; Tanaka K; Kainuma M; Nochioka K; Takagi A; Mimura M; Yamaguchi T; Ishii T
    Trials; 2020 Oct; 21(1):827. PubMed ID: 33008479
    [TBL] [Abstract][Full Text] [Related]  

  • 79. CovEMERALD: Assessing the feasibility and preliminary effectiveness of remotely delivered Eye Movement Desensitisation and Reprocessing following Covid-19 related critical illness: A structured summary of a study protocol for a randomised controlled trial.
    Bates A; Rushbrook S; Shapiro E; Grocott M; Cusack R
    Trials; 2020 Nov; 21(1):929. PubMed ID: 33203440
    [TBL] [Abstract][Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.